查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1621550

腫瘤消融市場：按技術、治療、適應症分類 - 全球預測 2025-2030

Tumor Ablation Market by Technology (Cryoablation, High-Intensity Focused Ultrasound, Irreversible Electroporation Ablation), Treatment (Laparoscopic Ablation, Percutaneous Ablation, Surgical Ablation), Indication - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年腫瘤消融市場價值為17.8億美元，預計2024年將達20.1億美元，複合年成長率為13.85%，到2030年將達44.2億美元。

腫瘤消融是指透過射頻消融術、冷凍、微波消融等方法破壞癌組織或腫瘤的微創手術。對腫瘤消融的需求源於癌症盛行率的不斷增加以及對侵入性較小、具有成本效益且對患者友好的治療方法的需求。其應用涵蓋腫瘤學，特別是肝癌、腎癌、肺癌和骨癌，這使得它在外科手術和姑息治療環境中都至關重要。最終用途範圍主要包括醫院、外科中心和癌症診所。市場成長受到技術進步的顯著影響，例如影像導引系統和消融技術的改進、癌症病例數量的增加以及對門診病人和非侵入性手術的偏好增加。此外，新興的潛在機會在於人工智慧和機器人技術的整合，以提高精確度，並將消融技術擴展到癌症發生率高的新興市場。抓住這些機會的建議包括投資混合技術的研發和擴大全球分銷網路。然而，新興市場認知度低、手術成本高以及潛在的術後併發症等限制因素可能會阻礙市場成長。其他挑戰包括嚴格的監管要求以及需要熟練的專業人員來執行這些高級程序。改進設備小型化和探索新能源方法等領域的創新和研究可以蓬勃發展。此外，提高我們對切除後腫瘤復發生物學的理解的研究將導致治療通訊協定的改進。總體而言，腫瘤消融市場是一個充滿活力的市場，其特點是技術快速進步，但受到監管和資源挑戰的限制。市場的性質要求注重創新、以患者為中心的方法和策略夥伴關係關係，以推動成長並克服現有障礙。

主要市場統計
基準年[2023] 17.8億美元
預測年份 [2024] 20.1億美元
預測年份 [2030] 44.2億美元
複合年成長率（%） 13.85%

市場動態：揭示快速發展的腫瘤消融市場的關鍵市場洞察

供需的動態交互作用正在改變腫瘤消融市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 癌症盛行率上升以及有效治療的需求
    • 擴大轉向微創手術切除腫瘤
    • 完善晚期癌症治療的報銷政策
  • 市場限制因素
    • 腫瘤消融裝置設計的複雜性
  • 市場機會
    • 全球腫瘤消融技術進展
    • 政府對腫瘤消融的有利核准
  • 市場挑戰
    • 對設備品質和安全的擔憂

波特五力：駕馭腫瘤消融市場的策略工具

波特五力是了解腫瘤消融市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解腫瘤消融市場的外部影響

外部宏觀環境因素在塑造腫瘤消融市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解腫瘤消融市場的競爭格局

對腫瘤消融市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV定位矩陣腫瘤消融市場供應商績效評估

FPNV定位矩陣是評估腫瘤消融市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了腫瘤消融市場的成功之路

腫瘤消融市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開發：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、未開發地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5.產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 癌症發生率上升以及有效治療方法的需求
      • 擴大轉向微創手術切除腫瘤
      • 完善晚期癌症治療的報銷政策
    • 抑制因素
      • 腫瘤消融裝置設計的複雜性
    • 機會
      • 全球腫瘤消融技術進展
      • 政府對腫瘤消融的有利核准
    • 任務
      • 對設備品質和安全的擔憂
  • 市場區隔分析
    • 治療：需要微創手術的患者的腹腔鏡消融術迅速增加
    • 適應症：加強使用腫瘤消融治療肺癌的研究
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章腫瘤消融市場：依技術分類

  • 冷凍療法
  • 高強度聚焦超音波
  • 不可逆電穿孔消融
  • 雷射組織內熱消融
  • 微波消融
  • 射頻消融術

第7章依治療方式分類的腫瘤消融市場

  • 腹腔鏡消融術
  • 經皮消融術
  • 手術消融

第8章按適應症分類的腫瘤消融市場

  • 乳癌
  • 腎癌
  • 肝癌
  • 肺癌
  • 攝護腺癌

第9章美洲腫瘤消融市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太腫瘤消融市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲腫瘤消融市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Medtronic)利用 FDA核准的OsteoCool 2.0 系統改善骨腫瘤治療
    • BioTraceIO 基於超音波的 BioTraceIO 獲得 FDA核准
    • FDA 授予 Francis Medical, Inc. 的蒸汽消融療法 Vanquish 突破性療法稱號
  • 戰略分析和建議

公司名單

  • Angiodynamics, Inc.
  • Bioventus LLC.
  • Boston Scientific Corp.
  • BVM Medical Limited
  • Chongqing Haifu Medical Technology Co., Ltd.
  • CONMED Corporation
  • CooperSurgical, Inc.
  • Erbe Elektromedizin GmbH
  • IceCure Medical Ltd.
  • Integra LifeSciences Corporation
  • Johnson & Johnson Services, Inc.
  • Medtronic PLC
  • Mermaid Medical A/S
  • Smith & Nephew PLC
  • Theraclion SA
Product Code: MRR-03252A5F927F

The Tumor Ablation Market was valued at USD 1.78 billion in 2023, expected to reach USD 2.01 billion in 2024, and is projected to grow at a CAGR of 13.85%, to USD 4.42 billion by 2030.

Tumor ablation refers to minimally invasive procedures designed to destroy cancerous tissue or tumors through methods such as radiofrequency ablation, cryoablation, and microwave ablation. The necessity of tumor ablation arises from the growing prevalence of cancer and the need for less invasive, cost-effective, and patient-friendly treatment options. Its application spans oncology, particularly for liver, kidney, lung, and bone cancers, making it essential in both operational and palliative care settings. The end-use scope primarily includes hospitals, surgical centers, and specialized cancer clinics. Market growth is significantly influenced by technological advancements such as image-guidance systems and improved ablation techniques, rising cancer cases, and an increasing preference for outpatient and non-invasive procedures. Additionally, the latest potential opportunities lie in the integration of AI and robotics for precision, as well as the expansion of ablation technologies into emerging markets with high cancer rates. A recommendation to seize these opportunities includes investing in R&D for hybrid technologies and expanding distribution networks globally. However, limitations such as the lack of awareness in developing regions, high procedural costs, and potential postoperative complications could hamper market growth. Other challenging factors include stringent regulatory requirements and the need for skilled professionals to perform these advanced procedures. Innovation and research could thrive in areas like improving device miniaturization and exploring novel energy modalities. Furthermore, research into better understanding the biology of tumor recurrence post-ablation can lead to enhanced treatment protocols. Overall, the tumor ablation market is dynamic, characterized by rapid technological advancement, yet constrained by regulatory and resource challenges. The nature of the market demands a focus on innovation, patient-centric approaches, and strategic partnerships to drive growth and overcome existing barriers.

KEY MARKET STATISTICS
Base Year [2023] USD 1.78 billion
Estimated Year [2024] USD 2.01 billion
Forecast Year [2030] USD 4.42 billion
CAGR (%) 13.85%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Tumor Ablation Market

The Tumor Ablation Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of cancer and need for effective treatments
    • Increasing shift to minimally invasive surgeries to remove tumors
    • Improvements in reimbursement policies for advanced cancer treatments
  • Market Restraints
    • Complexity of designing tumor ablation devices
  • Market Opportunities
    • Advancements in tumor ablation technologies worldwide
    • Favorable government approvals for tumor ablation
  • Market Challenges
    • Concerns associated with quality and safety of the device

Porter's Five Forces: A Strategic Tool for Navigating the Tumor Ablation Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Tumor Ablation Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Tumor Ablation Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Tumor Ablation Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Tumor Ablation Market

A detailed market share analysis in the Tumor Ablation Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Tumor Ablation Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Tumor Ablation Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Tumor Ablation Market

A strategic analysis of the Tumor Ablation Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Tumor Ablation Market, highlighting leading vendors and their innovative profiles. These include Angiodynamics, Inc., Bioventus LLC., Boston Scientific Corp., BVM Medical Limited, Chongqing Haifu Medical Technology Co., Ltd., CONMED Corporation, CooperSurgical, Inc., Erbe Elektromedizin GmbH, IceCure Medical Ltd., Integra LifeSciences Corporation, Johnson & Johnson Services, Inc., Medtronic PLC, Mermaid Medical A / S, Smith & Nephew PLC, and Theraclion S. A..

Market Segmentation & Coverage

This research report categorizes the Tumor Ablation Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Technology, market is studied across Cryoablation, High-Intensity Focused Ultrasound, Irreversible Electroporation Ablation, Laser Interstitial Thermal Ablation, Microwave Ablation, and Radiofrequency Ablation.
  • Based on Treatment, market is studied across Laparoscopic Ablation, Percutaneous Ablation, and Surgical Ablation.
  • Based on Indication, market is studied across Breast Cancer, Kidney Cancer, Liver Cancer, Lung Cancer, and Prostate Cancer.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of cancer and need for effective treatments
      • 5.1.1.2. Increasing shift to minimally invasive surgeries to remove tumors
      • 5.1.1.3. Improvements in reimbursement policies for advanced cancer treatments
    • 5.1.2. Restraints
      • 5.1.2.1. Complexity of designing tumor ablation devices
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in tumor ablation technologies worldwide
      • 5.1.3.2. Favorable government approvals for tumor ablation
    • 5.1.4. Challenges
      • 5.1.4.1. Concerns associated with quality and safety of the device
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Treatment: Exponential use of laparoscopic ablation for patients requiring minimally invasive surgery
    • 5.2.2. Indication: Increasing research in using tumor ablation for treating lung cancer
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Tumor Ablation Market, by Technology

  • 6.1. Introduction
  • 6.2. Cryoablation
  • 6.3. High-Intensity Focused Ultrasound
  • 6.4. Irreversible Electroporation Ablation
  • 6.5. Laser Interstitial Thermal Ablation
  • 6.6. Microwave Ablation
  • 6.7. Radiofrequency Ablation

7. Tumor Ablation Market, by Treatment

  • 7.1. Introduction
  • 7.2. Laparoscopic Ablation
  • 7.3. Percutaneous Ablation
  • 7.4. Surgical Ablation

8. Tumor Ablation Market, by Indication

  • 8.1. Introduction
  • 8.2. Breast Cancer
  • 8.3. Kidney Cancer
  • 8.4. Liver Cancer
  • 8.5. Lung Cancer
  • 8.6. Prostate Cancer

9. Americas Tumor Ablation Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Tumor Ablation Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Tumor Ablation Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Medtronic Elevates Bone Tumor Treatment with FDA-Approved OsteoCool 2.0 System
    • 12.3.2. BioTraceIO receives FDA Approval for Ultrasound-Based BioTraceIO
    • 12.3.3. FDA Grants Breakthrough Designation to Vanquish Water Vapor Ablation Therapy by Francis Medical, Inc.
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Angiodynamics, Inc.
  • 2. Bioventus LLC.
  • 3. Boston Scientific Corp.
  • 4. BVM Medical Limited
  • 5. Chongqing Haifu Medical Technology Co., Ltd.
  • 6. CONMED Corporation
  • 7. CooperSurgical, Inc.
  • 8. Erbe Elektromedizin GmbH
  • 9. IceCure Medical Ltd.
  • 10. Integra LifeSciences Corporation
  • 11. Johnson & Johnson Services, Inc.
  • 12. Medtronic PLC
  • 13. Mermaid Medical A / S
  • 14. Smith & Nephew PLC
  • 15. Theraclion S. A.

LIST OF FIGURES

  • FIGURE 1. TUMOR ABLATION MARKET RESEARCH PROCESS
  • FIGURE 2. TUMOR ABLATION MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL TUMOR ABLATION MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL TUMOR ABLATION MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL TUMOR ABLATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL TUMOR ABLATION MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL TUMOR ABLATION MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS TUMOR ABLATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS TUMOR ABLATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES TUMOR ABLATION MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES TUMOR ABLATION MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC TUMOR ABLATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC TUMOR ABLATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA TUMOR ABLATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA TUMOR ABLATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. TUMOR ABLATION MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. TUMOR ABLATION MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. TUMOR ABLATION MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL TUMOR ABLATION MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL TUMOR ABLATION MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL TUMOR ABLATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. TUMOR ABLATION MARKET DYNAMICS
  • TABLE 7. GLOBAL TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL TUMOR ABLATION MARKET SIZE, BY CRYOABLATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL TUMOR ABLATION MARKET SIZE, BY HIGH-INTENSITY FOCUSED ULTRASOUND, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL TUMOR ABLATION MARKET SIZE, BY IRREVERSIBLE ELECTROPORATION ABLATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL TUMOR ABLATION MARKET SIZE, BY LASER INTERSTITIAL THERMAL ABLATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL TUMOR ABLATION MARKET SIZE, BY MICROWAVE ABLATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL TUMOR ABLATION MARKET SIZE, BY RADIOFREQUENCY ABLATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL TUMOR ABLATION MARKET SIZE, BY LAPAROSCOPIC ABLATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL TUMOR ABLATION MARKET SIZE, BY PERCUTANEOUS ABLATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL TUMOR ABLATION MARKET SIZE, BY SURGICAL ABLATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL TUMOR ABLATION MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL TUMOR ABLATION MARKET SIZE, BY KIDNEY CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL TUMOR ABLATION MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL TUMOR ABLATION MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL TUMOR ABLATION MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS TUMOR ABLATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 37. MEXICO TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES TUMOR ABLATION MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 45. ASIA-PACIFIC TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 46. ASIA-PACIFIC TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC TUMOR ABLATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 48. AUSTRALIA TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 49. AUSTRALIA TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 50. AUSTRALIA TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 51. CHINA TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 52. CHINA TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 53. CHINA TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 54. INDIA TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 55. INDIA TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 56. INDIA TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 57. INDONESIA TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 58. INDONESIA TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 59. INDONESIA TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 60. JAPAN TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 61. JAPAN TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 62. JAPAN TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 63. MALAYSIA TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 64. MALAYSIA TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 65. MALAYSIA TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 66. PHILIPPINES TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 67. PHILIPPINES TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 68. PHILIPPINES TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 69. SINGAPORE TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 70. SINGAPORE TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 71. SINGAPORE TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 72. SOUTH KOREA TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 73. SOUTH KOREA TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 74. SOUTH KOREA TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 75. TAIWAN TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 76. TAIWAN TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 77. TAIWAN TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 78. THAILAND TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 79. THAILAND TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 80. THAILAND TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 81. VIETNAM TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 82. VIETNAM TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 83. VIETNAM TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA TUMOR ABLATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 88. DENMARK TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 89. DENMARK TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 90. DENMARK TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 91. EGYPT TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 92. EGYPT TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 93. EGYPT TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 94. FINLAND TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 95. FINLAND TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 96. FINLAND TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 97. FRANCE TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 98. FRANCE TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 99. FRANCE TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 100. GERMANY TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 101. GERMANY TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 102. GERMANY TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 103. ISRAEL TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 104. ISRAEL TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 105. ISRAEL TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 106. ITALY TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 107. ITALY TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 108. ITALY TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 109. NETHERLANDS TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 110. NETHERLANDS TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 111. NETHERLANDS TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 112. NIGERIA TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 113. NIGERIA TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 114. NIGERIA TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 115. NORWAY TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 116. NORWAY TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 117. NORWAY TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 118. POLAND TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 119. POLAND TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 120. POLAND TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 121. QATAR TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 122. QATAR TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 123. QATAR TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 124. RUSSIA TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 125. RUSSIA TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 126. RUSSIA TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 127. SAUDI ARABIA TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 128. SAUDI ARABIA TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 129. SAUDI ARABIA TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH AFRICA TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 131. SOUTH AFRICA TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 132. SOUTH AFRICA TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 133. SPAIN TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 134. SPAIN TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 135. SPAIN TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 136. SWEDEN TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 137. SWEDEN TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 138. SWEDEN TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 139. SWITZERLAND TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 140. SWITZERLAND TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 141. SWITZERLAND TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 142. TURKEY TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 143. TURKEY TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 144. TURKEY TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED ARAB EMIRATES TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED ARAB EMIRATES TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED ARAB EMIRATES TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 148. UNITED KINGDOM TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 149. UNITED KINGDOM TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 150. UNITED KINGDOM TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 151. TUMOR ABLATION MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 152. TUMOR ABLATION MARKET, FPNV POSITIONING MATRIX, 2023